{ "story_id": "edbd97d0fb74542dc61a530ba3380384", "desk": "drm3", "revision": 1, "published_at": "2026-09-02T02:46:06.000Z", "content_hash": "bb35d019002bd3210dc154ef78f1247830de6e953e4a207d5d526b382f9bb14a", "hash_basis": "sha256 over `headline\\ndek\\nprose`, plus `\\n` + the canonical citations JSON when any source is placed, plus `\\n#blog` for blogs", "basis": { "headline": "Trump expands drug pricing agenda with nine more pharmaceutical company deals", "dek": "President Trump announced nine additional drugmakers have joined 17 others in deals to cap U.S. drug prices at international levels.", "prose": "President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs. [^1]\n\nKyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more. [^2]\n\nThe stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program. [^3]\n\nHealth Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals. [^4]\n\nThe nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles. [^5]\n\nUCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals. [^6]\n\nA majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks. [^7]\n\nThe pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business. [^8]", "cited": "[{\"statement\":\"President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T19:48:44.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T02:46:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T02:46:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T19:48:44.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T19:48:44.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals.\",\"source\":\"STAT\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-08-31T19:48:44.000Z\",\"publisher_count\":1,\"sources\":[\"STAT\"]},{\"statement\":\"A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T02:46:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]},{\"statement\":\"The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business.\",\"source\":\"Investing.com\",\"instrument\":\"News\",\"claim_key\":null,\"published_at\":\"2026-09-02T02:46:06.000Z\",\"publisher_count\":1,\"sources\":[\"Investing.com\"]}]", "kind": "news" }, "receipt_verify": "Ed25519 over the dot-joined string `slice_hash.cursor_from.cursor_to.view.view_version.row_count`; public_key and sig are base64url of the raw 32-byte key / 64-byte signature", "receipt": null, "receipt_note": "this revision predates receipt-keeping (before v0.37.0); the filed row lives in the record", "generation_chain": { "wire": { "stream": "fountain_news", "story_id": "41de2cf83713a6c14924d9a99de62273", "thread_id": "5b27cc583b5b0479cfd68249b409a467", "thread_label": "Kyowa Kirin", "novelty": "UPDATE", "content_hash": "6b18e0a77ac70bcd13a0672a1b73d12624c8a7dc5dfa361eefa2ee2241b8a253", "last_published_at": "2026-09-02T02:46:06.000Z", "read_receipt": { "slice_hash": "e055356492cba8e6d7c27d5f31acf491bc3cadc19b402a5d3d43403f6d027a02", "cursor_from": "eyJ0cyI6IjIwMjYtMDktMDJUMDI6MDg6MzIuMDAwMDAwWiIsImlkIjoiMTdmNDIyN2UxZmE2ZjhhZDg5OGI1NDQzYzk3ZWQzYzciLCJ2IjoiMSJ9", "cursor_to": "eyJ0cyI6IjIwMjYtMDktMDJUMDM6MDA6MDAuMDAwMDAwWiIsImlkIjoiMjVhOGYxMWYxNTI1MjRlMTEyYjE1ZTc4YTc2YWM1MDEiLCJ2IjoiMSJ9", "view": "v_fountain_news", "view_version": "1", "row_count": 100, "window_days": 3, "bytes_scanned": 12017721, "credits": 8, "price_per_100_rows": 8, "sig": "MDxNd7HzwCw0Z4M4jwvvXKxFOkxlJwxaP-t4CRtfXprDv69fwXbKfrgSjFlawgUxotfSkn27zGc4hydaCa7lAw", "public_key": "bMUigy8O0jOnBxQ4Sc-5lwhIZ8LQVAhxMbR7qESVuUE", "signer_path": "lakehouse/data-extract/v1", "alg": "Ed25519", "signed": true } }, "written_at": "2026-09-02T22:31:17.822Z" }, "cited_facts": [ { "statement": "President Trump announced that nine additional drugmakers - Alcon, Astellas, BeOne, BridgeBio, CSL, Sun Pharma, Kyowa Kirin, Teva, and UCB - have joined 17 earlier companies in pricing agreements aimed at lowering U.S. drug costs.", "source": "STAT", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T19:48:44.000Z", "publisher_count": 1, "sources": [ "STAT" ] }, { "statement": "Kyowa Kirin stock fell 11.1% to trade at ¥2,390 during the session on September 2, giving back all of the prior day's gains and more.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T02:46:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "The stock decline occurred as the market digested the full implications of Kyowa Kirin's agreement with the Trump administration to lower drug prices in the U.S. Medicaid program.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T02:46:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "Health Secretary Robert F. Kennedy Jr. said on Monday that nine out of ten drugs prescribed in the U.S. are now covered by the pricing deals.", "source": "STAT", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T19:48:44.000Z", "publisher_count": 1, "sources": [ "STAT" ] }, { "statement": "The nine new companies pledged to sell new medications at prices comparable to the lowest in peer countries, offer Medicaid 'most-favored nation' pricing, and in some cases bolster domestic manufacturing and contribute to U.S. medical stockpiles.", "source": "STAT", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T19:48:44.000Z", "publisher_count": 1, "sources": [ "STAT" ] }, { "statement": "UCB, Sun Pharma, Teva, and Astellas will jointly contribute 290 metric tons of active pharmaceutical ingredients to the U.S. strategic reserves as part of the deals.", "source": "STAT", "instrument": "News", "claim_key": null, "published_at": "2026-08-31T19:48:44.000Z", "publisher_count": 1, "sources": [ "STAT" ] }, { "statement": "A majority of sell-side analysts covering the stock hold Sell or Underweight ratings, with consensus price targets sitting well below where the stock had been trading in recent weeks.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T02:46:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] }, { "statement": "The pricing arrangement is expanding to cover a broader list of pharmaceutical companies and products, raising concerns that mandated discounts could translate into material losses for Kyowa Kirin's North American business.", "source": "Investing.com", "instrument": "News", "claim_key": null, "published_at": "2026-09-02T02:46:06.000Z", "publisher_count": 1, "sources": [ "Investing.com" ] } ], "note": "A signature proves who filed this and that it has not changed since. It never makes a claim true." }